To include your compound in the COVID-19 Resource Center, submit it here.

Genentech rebuts Roche pessimism

Genentech rebuts Roche pessimism

Roche's criticism Genentech response
Future pricing - increases assumed Genentech assumed portfolio-weighted average price increases of about 3.6% in 2009, trending down to about optimistic 2.3% by 2015 due to factors that include the company's expectation of a potentially more challenging competitive and reimbursement environment. Moreover, according to the biotech: •Portfolio-weighted average

Read the full 592 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers